COMPANY:

Biomark Diagnostics

"BioMark Diagnostics Inc...announced&nb- sp;today a strategic Expression&nb- sp;of Interest (EOI) agreement&nbs- p;with SAMA CONSULTING SARL (- “SAMA CONSULTING“) to - explore the clinical application&n- bsp;of BioMark‘s innovative - liquid biopsy platform for lu- ng cancer detection initially - ;in Tunisia and later across&- nbsp;the broader North African&nbs- p;region."

"BioMark Diagnostics Inc...today announced the publication of a significant study exploring an artificial intelligence (AI) approach using novel graph neural networks (GNNs) that enhances the potential for early lung cancer diagnosis by modeling the complex web of metabolic pathways in cancer."

"BioMark Diagnostics Inc...today announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled “Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection”, provides significant external validation for BioMark’s metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions."

"BioMark Diagnostics...is pleased to announce that it has arranged and completed financing for the initial tranche of its non-brokered private placement (the “Private Placement”)...Demonstrating strong investor confidence in BioMark’s vision and technology, BioMark secured a USD $2 million investment from a pair of strategic investors based in the United States."

"BioMark Diagnostics Inc...announced a significant advancement in its breast cancer diagnostic capabilities. A groundbreaking study published in the International Journal of Molecular Sciences (IJMS) Special Edition demonstrates the potential of BioMark’s blood-based assay to accurately predict estrogen receptor (ER) status in breast cancer patients. This non-invasive test, leveraging metabolomics and machine learning, holds promise to revolutionize breast cancer diagnosis and treatment."

"BioMark Diagnostics Inc...today announced significant progress in its breast cancer program...Poster presentation on Lobular Breast Cancer Research...will be presenting the results from a retrospective study on early lobular breast cancer metabolomics panel during the Spotlight Poster Session 1 on Wednesday, December 11, 2024, Time: 12:30 PM – 2:00 PM at the Henry B. Gonzalez Convention Center, San Antonio, Texas."

"BioMark Diagnostics Inc...announce that its latest work, has been published in Cancers, titled Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms. This paper sheds light on the metabolic alterations that define pulmonary neuroendocrine neoplasms (NENs), focusing on identifying specific metabolomic biomarkers for early diagnosis and monitoring."

"BioMark Diagnostics Inc...announce that its latest work, has been published in Cancers, titled Metabolic Profiling of Pulmonary Neuroendocrine Neoplasms.This paper sheds light on the metabolic alterations that define pulmonary neuroendocrine neoplasms (NENs), focusing on identifying specific metabolomic biomarkers for early diagnosis and monitoring."

"BioMark Diagnostics Inc...today the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ). Over 5,400 patient samples were analyzed using BioMark’s innovative lung cancer assay, demonstrating the test’s potential to revolutionize early detection and improve patient outcomes."

"BioMark Diagnostics Inc...announce today that long time collaborators at the University of Manitoba Therapeutics will be presenting this week compelling new research findings on glioblastoma at the 2024 Globalization of Pharmaceutics Education Network (GPEN) Conference in Copenhagen from July 14-17, 2024."

"BioMark Diagnostics Inc...and Rubix LS...jointly announce today the signature of a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening program, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), by focusing on reaching underserved communities. This collaboration combines the innovative strengths of both organizations to develop accessible, non-invasive, and accurate diagnostic solutions that promise to set new standards in early detection and personalized cancer treatment."

"BioMark Diagnostics Inc...announce that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023."